237 related articles for article (PubMed ID: 32958253)
1. Blocking the interface region amongst S100A6 and RAGE V domain via S100B protein.
Sung HY; Dowarha D; Chou RH; Yu C
Biochem Biophys Res Commun; 2020 Dec; 533(3):332-337. PubMed ID: 32958253
[TBL] [Abstract][Full Text] [Related]
2. Blocking the interaction between S100A9 and RAGE V domain using CHAPS molecule: A novel route to drug development against cell proliferation.
Chang CC; Khan I; Tsai KL; Li H; Yang LW; Chou RH; Yu C
Biochim Biophys Acta; 2016 Nov; 1864(11):1558-69. PubMed ID: 27524699
[TBL] [Abstract][Full Text] [Related]
3. Blocking the Interactions between Calcium-Bound S100A12 Protein and the V Domain of RAGE Using Tranilast.
Chiou JW; Fu B; Chou RH; Yu C
PLoS One; 2016; 11(9):e0162000. PubMed ID: 27598566
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the S100A6 mutant (C3S) with the V domain of the receptor for advanced glycation end products (RAGE).
Mohan SK; Gupta AA; Yu C
Biochem Biophys Res Commun; 2013 May; 434(2):328-33. PubMed ID: 23537648
[TBL] [Abstract][Full Text] [Related]
5. Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain.
Khan MI; Dowarha D; Katte R; Chou RH; Filipek A; Yu C
PLoS One; 2019; 14(5):e0216427. PubMed ID: 31071146
[TBL] [Abstract][Full Text] [Related]
6. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains.
Leclerc E; Fritz G; Weibel M; Heizmann CW; Galichet A
J Biol Chem; 2007 Oct; 282(43):31317-31. PubMed ID: 17726019
[TBL] [Abstract][Full Text] [Related]
7. The Trp triad within the V-domain of the receptor for advanced glycation end products modulates folding, stability and ligand binding.
Indurthi VSK; Jensen JL; Leclerc E; Sinha S; Colbert CL; Vetter SW
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31912881
[TBL] [Abstract][Full Text] [Related]
8. The Structure of the RAGE:S100A6 Complex Reveals a Unique Mode of Homodimerization for S100 Proteins.
Yatime L; Betzer C; Jensen RK; Mortensen S; Jensen PH; Andersen GR
Structure; 2016 Dec; 24(12):2043-2052. PubMed ID: 27818100
[TBL] [Abstract][Full Text] [Related]
9. Tranilast Blocks the Interaction between the Protein S100A11 and Receptor for Advanced Glycation End Products (RAGE) V Domain and Inhibits Cell Proliferation.
Huang YK; Chou RH; Yu C
J Biol Chem; 2016 Jul; 291(27):14300-14310. PubMed ID: 27226584
[TBL] [Abstract][Full Text] [Related]
10. Circulating Ligands of the Receptor for Advanced Glycation End Products and the Soluble Form of the Receptor Modulate Cardiovascular Cell Apoptosis in Diabetes.
Tsoporis JN; Hatziagelaki E; Gupta S; Izhar S; Salpeas V; Tsiavou A; Rigopoulos AG; Triantafyllis AS; Marshall JC; Parker TG; Rizos IK
Molecules; 2020 Nov; 25(22):. PubMed ID: 33182705
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into the interaction of human S100B and basic fibroblast growth factor (FGF2): Effects on FGFR1 receptor signaling.
Gupta AA; Chou RH; Li H; Yang LW; Yu C
Biochim Biophys Acta; 2013 Dec; 1834(12):2606-19. PubMed ID: 24063890
[TBL] [Abstract][Full Text] [Related]
12. A fragment-based approach to discovery of Receptor for Advanced Glycation End products inhibitors.
Kozlyuk N; Gilston BA; Salay LE; Gogliotti RD; Christov PP; Kim K; Ovee M; Waterson AG; Chazin WJ
Proteins; 2021 Nov; 89(11):1399-1412. PubMed ID: 34156100
[TBL] [Abstract][Full Text] [Related]
13. S100B as an Antagonist To Interfere with the Interface Area Flanked by S100A11 and RAGE V Domain.
Dowarha D; Chou RH; Yu C
ACS Omega; 2018 Aug; 3(8):9689-9698. PubMed ID: 31459098
[TBL] [Abstract][Full Text] [Related]
14. S100B as an antagonist to block the interaction between S100A1 and the RAGE V domain.
Khan MI; Su YK; Zou J; Yang LW; Chou RH; Yu C
PLoS One; 2018; 13(2):e0190545. PubMed ID: 29444082
[TBL] [Abstract][Full Text] [Related]
15. Increased Expression of S100B and RAGE in a Mouse Model of Bile Duct Ligation-induced Liver Fibrosis.
Park JW; Kim MJ; Kim SE; Kim HJ; Jeon YC; Shin HY; Park SJ; Jang MK; Kim DJ; Park CK; Choi EK
J Korean Med Sci; 2021 Apr; 36(14):e90. PubMed ID: 33847081
[TBL] [Abstract][Full Text] [Related]
16. Differential gene expression analysis of RAGE-S100A6 complex for target selection and the design of novel inhibitors for anticancer drug discovery.
Faruqui T; Singh G; Khan S; Khan MS; Akhter Y
J Cell Biochem; 2023 Feb; 124(2):205-220. PubMed ID: 36502516
[TBL] [Abstract][Full Text] [Related]
17. A model of full-length RAGE in complex with S100B.
Moysa A; Steczkiewicz K; Niedzialek D; Hammerschmid D; Zhukova L; Sobott F; Dadlez M
Structure; 2021 Sep; 29(9):989-1002.e6. PubMed ID: 33887170
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of recombinant human S100A6 and soluble receptor for advanced glycation end products(sRAGE) on CCl
Xia P; He H; Kristine MS; Guan W; Gao J; Wang Z; Hu J; Han L; Li J; Han W; Yu Y
Eur J Pharmacol; 2018 Aug; 833():86-93. PubMed ID: 29800549
[TBL] [Abstract][Full Text] [Related]
19. Blocking the interaction between S100A9 protein and RAGE V domain using S100A12 protein.
Katte R; Yu C
PLoS One; 2018; 13(6):e0198767. PubMed ID: 29902210
[TBL] [Abstract][Full Text] [Related]
20. X-ray crystal structure of human calcium-bound S100A1.
Melville Z; Aligholizadeh E; McKnight LE; Weber DJ; Pozharski E; Weber DJ
Acta Crystallogr F Struct Biol Commun; 2017 Apr; 73(Pt 4):215-221. PubMed ID: 28368280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
